Shots:

• Verastem will receive an upfront of $15M with up to $30M for development milestones- additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib)
• CSPC to get exclusive development and commercialization rights of Copiktra in China and will also assist Verastem in R&D activities globally on cost sharing basis
• Copiktra is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase)- first approved dual inhibitor of PI3K-delta and PI3K-gamma and received approval from FDA for the treatment of r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies

    Ref: Verastem Oncology | Image: Wall Street